CYCN
Cyclerion Therapeutics, Inc. Common Stock
PHARMACEUTICAL PREPARATIONS
Best Pharmaceutical Stocks 2026 →
Cyclerion Therapeutics (CYCN) Stock: Buy, Sell, or Hold?
$3.36
-0.89 (-20.94%)
âŧ
5d:
-8.7%
30d:
-5.88%
90d:
+11.63%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (64%)
Quality Score
46/100
Position
FAIR
Forward P/E & Valuation
-3.4x
Next 12M consensus est.
Wall Street Target
$8.00
+138.1% upside
Options IV & Volume
UNKNOWN Vol
UNKNOWN volume confirmation
Support / Resistance
$2.82 / $5.19
Trend: Support Break
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
âšī¸ NEUTRAL: CYCN is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
Get Alerted When CYCN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: CYCN is currently trading at $3.36, which is considered fair based on recent price action.
Technical Outlook: Technically, CYCN is showing support break momentum. Immediate support is located at $2.82, while resistance sits at $5.19. Short-term momentum is weak, with the stock down 20.9% recently.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $8.00 (+138.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CYCN is showing support break momentum. Immediate support is located at $2.82, while resistance sits at $5.19. Short-term momentum is weak, with the stock down 20.9% recently.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $8.00 (+138.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Company Quality Score
46/100
(HOLD)
Volume Confirmation
UNKNOWN
Confidence Score
64.2%
Trading Range & Key Levels
Support Level
$2.82
Resistance Level
$5.19
Current Trend
Support Break
Technical data as of
Sep 8, 2026
Quantitative Signal Breakdown
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BEARISH: Downward momentum (-20.9%)
- BULLISH: Trading 138.1% below Wall St target ($8.00)
- WARNING: Composite score 46/100 in the bottom quintile â this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
-3.39
Wall Street Target
$8.00
(+138.1%)
Revenue Growth (YoY)
-43.2%
Share CYCN Analysis
Share this live CYCN analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (CYCN)
Bullish
1 Retail Mentions
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Aug 15, 2026
Daily AI digest
AI Retail Discussion Summary:
A bullish StockTwits message suggests a trader has added a position in $CYCN in anticipation of a merger vote.
Key Retail Themes:
Merger activity
Buyer sentiment
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 12, 2026 11:55 PM ET
Data refreshes hourly during market hours. Next update: 12:55 AM
Data refreshes hourly during market hours. Next update: 12:55 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CYCN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
24 analysts |
$145 | 37 SELL |
|
ARGX
argenx NV ADR |
STRONG BUY
23 analysts |
$1147 | 31 SELL |
|
DNTH
Dianthus Therapeutics InâĻ |
STRONG BUY
18 analysts |
$139 | 41 HOLD |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 39 SELL |
|
SYRE
Spyre Therapeutics Inc. |
STRONG BUY
18 analysts |
$122 | 44 HOLD |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive CYCN Research Pages
